VIRMA and prostate cancer: Indeed, in glioblastoma and hepatocellular carcinoma, METTL14 downregulation associated with m6A levels reduction [40, 43], while VIRMA upregulation positively correlated with higher m6A levels, in both testicular germ cell tumors and prostate cancer [21, 22].